Abstract:Objective Nipocalimab is a neonatal fragment crystallizable (Fc) receptor (FcRn)—blocking monoclonal antibody that inhibits placental immunoglobulin G (IgG) transfer and lowers circulating maternal IgG levels. In an open-label, single-arm, phase 2 study, nipocalimab demonstrated evidence of safety and efficacy that support further investigation in a pivotal phase 3 trial of recurrent hemolytic disease of the fetus and newborn (HDFN). The phase 3 AZALEA study aims to evaluate the efficacy and safety of nipocalimab in a larger population at risk for severe HDFN, defined as HDFN associated with poor fetal outcomes or neonatal death. Study Design AZALEA is a multicenter, randomized, placebo-controlled, double-blind, phase 3 study enrolling alloimmunized pregnant individuals ( N ≈ 120) at risk for severe HDFN based on obstetric history. Participants are randomized 2:1 to receive intravenous 45 mg/kg nipocalimab or placebo weekly from 13–16 to 35 weeks gestational age (GA). During the double-blind treatment period, participants receive standard-of-care weekly monitoring for fetal anemia until planned delivery at 37 to 38 weeks of GA. Postnatal follow-up periods are 24 weeks for maternal participants and 104 weeks for neonates/infants. Results The primary endpoint is the proportion of pregnancies that do not result in intrauterine transfusion (IUT), hydrops fetalis, or fetal loss/neonatal death from all causes. Key secondary endpoints include the severity of HDFN as measured by a composite HDFN severity index, the earliest time to occurrence of IUT or hydrops fetalis, the modified neonatal mortality and morbidity index in liveborn neonates, and the number of IUTs received. Other endpoints are safety, patient- and caregiver-reported outcomes, pharmacokinetics, pharmacodynamics (e.g., IgG, FcRn receptor occupancy), and immunogenicity of nipocalimab. Conclusion AZALEA, the first placebo-controlled, randomized, multicenter, prospective trial in severe HDFN, is designed to evaluate the safety and efficacy of nipocalimab, a potential preventive and noninvasive intervention, in at-risk HDFN pregnancies. Key Points Severe HDFN leads to poor fetal/neonatal outcomes. IUTs are associated with complications and fetal loss. Nipocalimab blocks IgG recycling and placental transfer. Nipocalimab reduces fetal anemia and IUTs in early-onset severe HDFN. The phase 3 AZALEA study evaluates nipocalimab in severe HDFN. This study is registered with ClinicalTrials.gov Identifier: NCT05912517. EudraCT Number: 2021-002359-12. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05912517 . Date of registration: June 22, 2023. Received: 10 May 2024 Accepted: 22 August 2024 Accepted Manuscript online: 28 August 2024 Article published online: 17 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Identifying Hemolytic Disease of the Fetus and Newborn within a Large Integrated Health Care System

Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States

Severe Neonatal Anemia Affected by Massive Fetomaternal Hemorrhage: a Single-Center Retrospective Observational Study

Neonatal and Obstetrical Outcomes of Pregnancies Complicated by Alloimmunization

Maternal red blood cell alloimmunization prevalence in the United States

Medical, Administrative, Financial, and Social Challenges in the Management of a Case of Hemolytic Disease of the Fetus Caused by a Rare Alloantibody in a Low-Resource Setting

A Clinical Outcomes Data Archive for a Comprehensive Fetal Diagnosis and Treatment Center

Prevalence of alloantibodies associated with haemolytic disease of the fetus and newborn in pregnant women at the Ekiti State University Teaching Hospital, Ado-Ekiti, Southwest Nigeria

Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn

Prevalence of unexpected red blood cell antibodies in pregnant women and follow-up of pregnancy outcome in pregnant women treated with intra-uterine transfusion

Distribution of maternal red cell antibodies and the risk of severe alloimmune haemolytic disease of the foetus in a Chinese population: a cohort study on prenatal management

Another piece of the hemolytic disease of the fetus and newborn puzzle after RhD-positive transfusion in trauma resuscitation: the proportion of pregnant women who produce high titer anti-D

Hemolytic disease of the fetus and newborn due to alloanti-M: three Chinese case reports and a review of the literature.

A challenging case of hemolytic disease of the fetus and newborn (HDFN) due to anti-Ku in a K0 (Kellnull) mother

Clinical analysis of non-immune hydrops in 10 fetuses

How I manage pregnant patients who are alloimmunized to RBC antigens

Hemolytic disease of the fetus and newborn: pregnant person's and fetal immune systems interaction

[Retrospective Analysis of Irregular Antibodies Causing Hemolytic Disease of the Fetus and Newborn in Jiangxi Province]

Hyporegenerative Anemia in Anti-M-associated Hemolytic Disease of the Fetus.

Outcome and etiology of fetal pleural effusion, fetal ascites and hydrops fetalis after fetal intervention: retrospective observational cohort from a single institution

Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy